We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Deciphera (DCPH) Secures Early FDA Nod for GIST Drug Qinlock
Read MoreHide Full Article
Deciphera Pharmaceuticals, Inc. (DCPH - Free Report) announced that the FDA has approved its kinase inhibitor Qinlock (ripretinib) for treating patients with advanced gastrointestinal stromal tumors (GIST) who were already treated with three or more kinase inhibitors including Novartis’ (NVS - Free Report) Gleevec (imatinib).
In February 2020, the FDA accepted the new drug application (NDA) for Qinlock to treat patients with fourth-line GIST. In December 2019, the NDA application was filed for the same.
In August last year, the company announced encouraging data from the INVICTUS study evaluating Qinlock in GIST patients, previously treated with at least Novartis’ Gleevec, Pfizer’s (PFE - Free Report) Sutent (sunitinib) and Bayer’s (BAYRY - Free Report) Stivarga (regorafenib).
Shares of Deciphera have declined 10.4% so far this year against the industry’s increase of 7.7%.
We note that the approval comes three months before the scheduled Prescription Drug User Fee Act (PDUFA) action date of Aug 13, 2020. The NDA for Qinlock was also granted Breakthrough Therapy and Fast Track designations as well as a priority review under the Real-Time Oncology Review pilot program of the FDA.
Per the company, this approval was based on the efficacy data from the pivotal phase III INVICTUS study as well as the combined safety results from INVICTUS and the phase I study on Qinlock in patients with advanced GIST. Outcomes of the study showed that treatment with Qinlock led to a median progression-free survival of 6.3 months compared to one month in the placebo arm. Findings also reflect a significant reduction in the risk of disease progression or death by 85%.
Moreover, Qinlock demonstrated a median overall survival of 15.1 months compared to 6.6 months in the placebo arm, thereby reducing the risk of death by 64%.
The company plans to launch the drug shortly in the United States.
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
Image: Bigstock
Deciphera (DCPH) Secures Early FDA Nod for GIST Drug Qinlock
Deciphera Pharmaceuticals, Inc. (DCPH - Free Report) announced that the FDA has approved its kinase inhibitor Qinlock (ripretinib) for treating patients with advanced gastrointestinal stromal tumors (GIST) who were already treated with three or more kinase inhibitors including Novartis’ (NVS - Free Report) Gleevec (imatinib).
In February 2020, the FDA accepted the new drug application (NDA) for Qinlock to treat patients with fourth-line GIST. In December 2019, the NDA application was filed for the same.
In August last year, the company announced encouraging data from the INVICTUS study evaluating Qinlock in GIST patients, previously treated with at least Novartis’ Gleevec, Pfizer’s (PFE - Free Report) Sutent (sunitinib) and Bayer’s (BAYRY - Free Report) Stivarga (regorafenib).
Shares of Deciphera have declined 10.4% so far this year against the industry’s increase of 7.7%.
We note that the approval comes three months before the scheduled Prescription Drug User Fee Act (PDUFA) action date of Aug 13, 2020. The NDA for Qinlock was also granted Breakthrough Therapy and Fast Track designations as well as a priority review under the Real-Time Oncology Review pilot program of the FDA.
Per the company, this approval was based on the efficacy data from the pivotal phase III INVICTUS study as well as the combined safety results from INVICTUS and the phase I study on Qinlock in patients with advanced GIST. Outcomes of the study showed that treatment with Qinlock led to a median progression-free survival of 6.3 months compared to one month in the placebo arm. Findings also reflect a significant reduction in the risk of disease progression or death by 85%.
Moreover, Qinlock demonstrated a median overall survival of 15.1 months compared to 6.6 months in the placebo arm, thereby reducing the risk of death by 64%.
The company plans to launch the drug shortly in the United States.
Zacks Rank
Deciphera currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
See their latest picks free >>